rhBMP-2/CPM as an Adjuvant Therapy for Femur Fractures
ID Number 06-1239Principal Investigator(s)
Edward C. Yang
Department(s) or Division(s)
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is an osteoinductive protein that directs uncommitted mesenchymal cells to differentiate into osteoblasts. The sequence of cellular events observed following injection of rhBMP-2 is similar to that observed in normal fracture repair and embryonic endochondral bone formation. The primary objective is to • To demonstrate the safety of administering rhBMP-2/CPM (either 1.0 mg/mL or 2.0 mg/mL) as an adjunct to internal fixation in subjects with fractures of the proximal femur. The key safety outcome is the incidence of secondary fracture displacement among subjects treated with rhBMP-2/CPM and those receiving standard surgical treatment (internal fixation) alone.
Recruiting Patients: Yes